This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:
Applied Digital ($APLD) Secures $7 Billion AI Data Center Lease With CoreWeave
Applied Digital ($APLD), a designer and operator of next-generation digital infrastructure, announced it has signed two approximately 15-year lease agreements with AI cloud company CoreWeave for its Ellendale, North Dakota data center campus. Under the agreements, Applied Digital will deliver 250 megawatts (MW) of critical IT load to host CoreWeave’s artificial intelligence (AI) and high-performance computing (HPC) infrastructure.
According to the company, the leases are expected to generate approximately $7 billion in total revenue over the term, marking a major step in Applied Digital’s strategy to scale its AI-focused data center operations. CoreWeave also retains an option to access an additional 150 MW of capacity at the campus.
Applied Digital’s Ellendale campus, purpose-built for AI and HPC workloads, is positioned to eventually scale to 1 gigawatt of power capacity. The first 100 MW facility for CoreWeave is slated to be ready by the fourth quarter of 2025, with a second 150 MW facility expected to come online by mid-2026. A third building remains in planning stages with a target service date in 2027, subject to CoreWeave exercising its expansion option.
In a statement, Applied Digital’s CEO Wes Cummins said the deal positions the company as an emerging provider of essential infrastructure for the AI sector. The Ellendale campus, according to Applied Digital, is designed with high-density compute capabilities, access to low-cost energy, and a scalable footprint to meet the surging demand for AI data center capacity.
Stock Price Movement
$APLD stock surged 48.5% following the announcement, reflecting investor enthusiasm for the company’s deepening ties to the booming AI infrastructure market.
Tempus ($TEM) Unveils New Liquid Biopsy Test for Cancer Immunotherapy Monitoring
Tempus AI, Inc. ($TEM), a technology company applying AI to advance precision medicine, announced the introduction of xM for Treatment Response Monitoring (TRM), a new liquid biopsy assay designed to monitor how patients with advanced cancers respond to immune-checkpoint inhibitor (ICI) therapies.
According to the company, xM for TRM quantifies changes in circulating tumor DNA (ctDNA) over time through a blood sample, providing an early molecular response assessment. Tempus stated the assay integrates copy number variations (CNVs) and variant allele frequencies (VAFs) through a multi-parametric algorithm to offer a comprehensive view of tumor burden dynamics. The test is currently available for research use only, with clinical availability anticipated later in 2025.
Tempus highlighted that in 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, but only about 20.13% responded to the treatment. xM for TRM aims to fill a critical gap by enabling earlier detection of treatment response, which could help optimize therapeutic strategies.
The company is showcasing new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, underlining its potential to improve patient outcomes by allowing clinicians to detect molecular responses as early as six weeks into treatment.
Stock Price Movement
$TEM stock rose 15% following the announcement.
Hims & Hers ($HIMS) to Acquire ZAVA, Expanding in Europe
Hims & Hers Health, Inc. ($HIMS), a consumer health platform focused on personalized care, announced plans to acquire ZAVA, a leading digital healthcare provider operating across the UK, Germany, France, and Ireland. The move marks a major step in Hims & Hers’ international expansion strategy, strengthening its presence in key European markets.
ZAVA, founded in 2011, has served over 7 million patients through its telemedicine platform, providing services in areas such as primary care, sexual health, and chronic condition management. The acquisition aligns with Hims & Hers’ long-term strategy to build a broad global healthcare footprint by expanding its direct-to-consumer model beyond the U.S.
According to Hims & Hers, the acquisition of ZAVA is expected to accelerate its growth across Europe, leveraging ZAVA’s existing regulatory infrastructure, medical networks, and patient trust. The company stated that this move will enable it to offer a wider range of services to a broader patient population, while continuing to prioritize accessible, affordable, and personalized healthcare solutions.
Financial terms of the transaction were not disclosed. Hims & Hers indicated that the deal is subject to customary closing conditions and regulatory approvals, with closing expected later this year.
ZAVA’s CEO and founder, Dr. David Meinertz, commented, “By joining forces with Hims & Hers, we can scale our mission of delivering simple and convenient healthcare even faster across Europe.”
Hims & Hers added that it sees the European market as a major opportunity, citing rising demand for digital health services and favorable healthcare access trends. The company plans to build on ZAVA’s footprint to introduce its subscription-based care model to millions of potential new customers.
Stock Price Movement
$HIMS stock experienced a volatile trading session, rising as much as 15% intraday following the announcement but ultimately closing down 3.6%.
This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.
